Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01169610 · ClinicalTrials.gov registry record · Phase 3
Varenicline and Alcohol in Inpatient Addictions Program (IAP)
A Phase 3 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1
- Enrollment target
NCT01169610: Clinical Trial Phase 3 study, sponsored by Mayo Clinic.
NCT01169610 is a Phase 3 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 1 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01169610, a Phase 3 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1 participants
- Enrollment target
Study Summary
The overall hypothesis of this line of research is that varenicline will decrease alcohol consumption and tobacco use and will increase alcohol and tobacco abstinence rates. In order to explore this hypothesis, the investigators will conduct a two-phase study: 1) an open label pilot study investigating the effect of varenicline on reduction of and abstinence from alcohol and tobacco; and 2) an optional MR spectroscopy to investigate whether glutamate and other brain metabolites correlate to measures of alcohol craving severity and/or subsequent varenicline treatment response.
Primary Outcome
No consumption of alcohol (not even a single drink) during the specified interval of time. This will be a self-reported outcome.
Interventions
- DRUG Varenicline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2011-01 |
| Est. Completion | 2013-06 |
| Phase | Phase 3 |
Why NCT01169610 stopped before completion
NCT01169610 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Varenicline is the first listed.
NCT01169610 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01169610 about?
NCT01169610 is a clinical study titled "Varenicline and Alcohol in Inpatient Addictions Program (IAP)". The overall hypothesis of this line of research is that varenicline will decrease alcohol consumption and tobacco use and will increase alcohol and tobacco abstinence rates. In order to explore this hypothesis, the investigators will conduct a two-phase study: 1) an open label pilot study investigat...
What is the current status of trial NCT01169610?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1 participants. The study started on 2011-01. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01169610?
The interventions under investigation include: Varenicline (DRUG).
Who is sponsoring clinical trial NCT01169610?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01169610's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia